D-SOLVE Cohorts (Cohort a and B)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHannover Medical School

About this trial

Hepatitis D is by far the most severe form of chronic viral hepatitis, frequently leading to liver failure, hepatocellular carcinoma and death. Hepatitis D is caused by coinfection Hepatitis D is caused by co-infection with hepatitis B virus (HBV) and hepatitis D virus (HDV).

This multicenter cohort should enable a comprehensive and unbiased biomarker screening of well-defined HDV-infected patients, followed by mechanistic studies to determine the functional role of distinct molecules. Patient surveillance strategies and antiviral treatment approaches could be personalized which should reduce clinical and social disease burden, improve quality of life and save direct and indirect costs caused by HDV infection.

Eligibility criteria

Qualifiers

Anti-HDV positive

≥18 years old

Sex: m/f/d

Informed consent for prospective procedures

Disqualifiers

Anti-HDV negative

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

750 Participants
are grouped into 2 trial groups

Locations

4
Germany
Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Disease and Endocrinology30625, Hanover Germany
Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (University of Milan) Milan Italy
Romania
Institutul de Boli Infectioase "Prof. Dr. Matei Bals"021105, Bucharest Romania
Sweden
Karolinska University Hospital and Karolinska Institutet Stockholm Sweden

Sponsors and collaborators

Hannover Medical School

Lead sponsor

Karolinska University Hospital

Collaborator

Karolinska Institutet

Collaborator

Helmholtz Centre for Infection Research

Collaborator

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Collaborator

National Institute of Infectious Diseases Matei Bals

Collaborator